GMED vs PTGX
Globus Medical vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
PTGX
Protagonist Therapeutics, Inc.
65
Buy
| Metric | GMED | PTGX |
|---|
| AI Score |
71
|
65
|
| Price |
$85.12
|
$148.25
|
| P/E Ratio |
21.45×
|
121.74×
|
| ROE |
11.8%
|
-21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
99.9%
|
| Debt / Equity |
0.02×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
75.9
|
68.1
|
| Beta |
0.954
|
1.794
|
| Expected Upside |
+0.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for GMED versus PTGX.
GMED leads by 6 points.
GMED scores 71/100 (Buy) versus PTGX at 65/100 (Buy).
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
PTGX Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 115.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical